Published in Dialogues Clin Neurosci on January 01, 2006
Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas (2014) 1.17
Substance dependence: Decades apart in a teaching hospital. Indian J Psychiatry (2008) 1.09
The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological study. Br J Clin Pharmacol (2008) 0.93
nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives. Schizophr Res (2016) 0.84
Effects of smoking cues on caffeine urges in heavy smokers and caffeine consumers with and without schizophrenia. Schizophr Res (2008) 0.83
Overview and initial validation of two detailed, multidimensional, retrospective measures of substance use: the Lifetime Substance Use Recall (LSUR) and Longitudinal Substance Use Recall for 12 Weeks (LSUR-12) Instruments. J Psychiatr Res (2010) 0.81
Cortical grey matter volume reduction in people with schizophrenia is associated with neuro-inflammation. Transl Psychiatry (2016) 0.79
Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats. Psychopharmacology (Berl) (2012) 0.77
A retrospective analysis focusing on a group of patients with dual diagnosis treated by both mental health and substance use services. Neuropsychiatr Dis Treat (2014) 0.76
The effectiveness of treatments for cocaine dependence in schizophrenic patients: a systematic review. Curr Neuropharmacol (2013) 0.76
Drug Addiction in Patients With Chronic Schizophrenia and Its Relation With Psychopathology and Impulsiveness. Glob J Health Sci (2015) 0.75
Non-adherence and its consequences: understanding the nature of relapse. World Psychiatry (2013) 0.75
Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA (1990) 17.70
Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry (2003) 7.11
Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry (2004) 5.95
Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress. Am J Psychiatry (2005) 4.01
Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet (1987) 3.61
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ (2002) 3.06
Cannabis use and the risk of later schizophrenia: a review. Addiction (2004) 2.98
Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology (1998) 2.96
The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology (2004) 2.87
A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry (2001) 2.58
Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry (1992) 2.24
Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res (1999) 2.19
Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry (1993) 2.17
Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry (1994) 2.06
Tests of causal linkages between cannabis use and psychotic symptoms. Addiction (2005) 2.02
Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol (2005) 1.79
Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology (1996) 1.62
Substance abuse and the onset of schizophrenia. Biol Psychiatry (1996) 1.55
Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. Am J Psychiatry (2004) 1.42
Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry (2004) 1.33
Nicotine dependence and schizophrenia. Hosp Community Psychiatry (1994) 1.32
Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry (2005) 1.29
Substance abuse in schizophrenia: a review. J Clin Psychiatry (1998) 1.23
Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry (1999) 1.21
Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. Can J Psychiatry (2004) 1.15
Compounded brain volume deficits in schizophrenia-alcoholism comorbidity. Arch Gen Psychiatry (2003) 1.04
A brief motivational intervention for substance misuse in recent-onset psychosis. Drug Alcohol Rev (2004) 1.02
Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res (1999) 1.00
Unrecognized cocaine use among schizophrenic patients. Am J Psychiatry (1993) 1.00
Substance misuse in patients with schizophrenia: epidemiology and management. Drugs (2002) 0.97
Women with co-occurring addictive and mental disorders: an emerging profile of vulnerability. Am J Orthopsychiatry (1996) 0.97
The incarceration of individuals with severe mental disorders. Community Ment Health J (2001) 0.88
Schizophrenia and comorbid substance use disorder: effects of antipsychotics. J Clin Psychiatry (2005) 0.85
Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis (2005) 0.85
Adolescence, schizophrenia and drug abuse: a window of vulnerability. Acta Psychiatr Scand Suppl (2005) 0.82
[Cognitive dysfunction in schizophrenic psychoses. Drug and psychological treatment choices]. Psychiatr Prax (2001) 0.80
Schizophrenia, substance use disorders and medical co-morbidity. J Ment Health Policy Econ (2000) 0.79
The cannabis and psychosis connection questioned: a comment on Fergusson et al. 2005. Addiction (2005) 0.78
Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med (2010) 3.84
Lithium in drinking water and suicide mortality. Br J Psychiatry (2011) 2.02
Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat (2008) 1.77
Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. Addiction (2005) 1.57
A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology (2008) 1.56
Influence of site differences between urban and rural American and Central European opioid-dependent pregnant women and neonatal outcome characteristics. Eur Addict Res (2012) 1.56
Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction (2008) 1.51
Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and methadone tapers: can we assure the safety of the fetus? J Matern Fetal Neonatal Med (2012) 1.43
Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend (2003) 1.36
Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend (2006) 1.31
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction (2012) 1.25
A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes. Subst Abuse (2013) 1.16
Anxiety as a predictor of relapse in detoxified alcohol-dependent patients. Alcohol Alcohol (2002) 1.14
Unintended pregnancy in opioid-abusing women. J Subst Abuse Treat (2010) 1.14
Maternal Opioid Treatment: Human Experimental Research (MOTHER)--approach, issues and lessons learned. Addiction (2012) 1.13
Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction (2003) 1.11
Cocaine use in Europe - a multi-centre study. Methodology and prevalence estimates. Eur Addict Res (2004) 1.10
Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr Bull (2014) 1.10
Association between prenatal tobacco exposure and outcome of neonates born to opioid-maintained mothers. Implications for treatment. Eur Addict Res (2009) 1.07
Quality of life in patients receiving opioid maintenance therapy. A comparative study of slow-release morphine versus methadone treatment. Eur Addict Res (2008) 1.03
Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine. J Addict Dis (2010) 1.03
Cocaine use in Europe - a multi-centre study: patterns of use in different groups. Eur Addict Res (2004) 1.03
Multiple substance use among young males. Pharmacol Biochem Behav (2006) 0.98
Co-occurring psychiatric symptoms are associated with increased psychological, social, and medical impairment in opioid dependent pregnant women. Am J Addict (2010) 0.95
Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women. Hum Psychopharmacol (2011) 0.94
First-trimester fetal heart rate in mothers with opioid addiction. Addiction (2010) 0.94
Characteristics of opioid-using pregnant women who accept or refuse participation in a clinical trial: screening results from the MOTHER study. Am J Drug Alcohol Abuse (2009) 0.93
Psychopharmacologic management of opioid-dependent women during pregnancy. Am J Addict (2009) 0.92
No strong evidence for abnormal levels of dysfunctional attitudes, automatic thoughts, and emotional information-processing biases in remitted bipolar I affective disorder. Psychol Psychother (2008) 0.91
Age-related aspects of addiction. Gerontology (2012) 0.89
Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients. Addict Biol (2009) 0.89
Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction (2012) 0.88
Opioid dependent and pregnant: what are the best options for mothers and neonates? Obstet Gynecol Int (2012) 0.88
Molecular cloning and heterologous expression of progesterone 5beta-reductase from Digitalis lanata Ehrh. Phytochemistry (2005) 0.88
Opioid addiction changes cerebral blood flow symmetry. Neuropsychobiology (2002) 0.87
Opioid dependence and pregnancy. Curr Opin Psychiatry (2008) 0.87
Office-based treatment in opioid dependence: a critical survey of prescription practices for opioid maintenance medications and concomitant benzodiazepines in Vienna, Austria. Eur Addict Res (2008) 0.86
Randomized controlled trials in pregnancy: scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison. Addiction (2011) 0.85
Maintenance therapy with synthetic opioids and driving aptitude. Eur Addict Res (2004) 0.84
Use of slow-release oral morphine for the treatment of opioid dependence. Eur Addict Res (2005) 0.83
Relationship between cocaine use and mental health problems in a sample of European cocaine powder or crack users. World Psychiatry (2005) 0.83
Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. Neuropsychopharmacology (2008) 0.82
[Cocaine abuse in Vienna and European cities--a multi-center study]. Wien Klin Wochenschr (2006) 0.81
Opioid plasma concentrations in methadone-and buprenorphine-maintained patients. Addict Biol (2005) 0.81
Mortality in opioid-maintained patients after release from an addiction clinic. Eur Addict Res (2008) 0.81
Glutamic acid in withdrawal and weaning in patients classified according to Cloninger's and Lesch's typologies. Alcohol Alcohol (2006) 0.81
[123I]-beta-CIT SPECT imaging shows reduced thalamus-hypothalamus serotonin transporter availability in 24 drug-free obsessive-compulsive checkers. Neuropsychopharmacology (2006) 0.81
Buprenorphine maintenance: office-based treatment with addiction clinic support. Eur Addict Res (2004) 0.81
Influence of peak and trough levels of opioid maintenance therapy on driving aptitude. Eur Addict Res (2007) 0.80
Breath alcohol level and plasma amino acids: a comparison between older and younger chronic alcohol-dependent patients. Alcohol Alcohol (2008) 0.80
Cognitive and emotion recognition deficits in obsessive-compulsive disorder. Psychiatry Res (2006) 0.80
Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Hum Psychopharmacol (2012) 0.80
[Slow-release morphine hydrochloride for maintenance therapy of opioid dependence]. Wien Klin Wochenschr (2002) 0.79
Backbone and sidechain (1)H, (15)N and (13)C assignments of the NLRP7 pyrin domain. Biomol NMR Assign (2009) 0.79
[Addiction--who is not affected?]. Wien Med Wochenschr (2005) 0.78
Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug Alcohol Depend (2013) 0.78
Characteristics and quality of life of opioid-dependent pregnant women in Austria. Arch Womens Ment Health (2014) 0.78
Opioid dependence during pregnancy: relationships of anxiety and depression symptoms to treatment outcomes. Addiction (2012) 0.78
Personality disorder and social anxiety predict delayed response in drug and behavioral treatment of panic disorder. J Affect Disord (2004) 0.77
Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates? Gend Med (2011) 0.77
Policy drives harm reduction for drug abuse and HIV/AIDS prevention in some developing countries. Drug Alcohol Depend (2007) 0.77
Diencephalic serotonin transporter availability predicts both transporter occupancy and treatment response to sertraline in obsessive-compulsive checkers. Biol Psychiatry (2009) 0.76
Molecular cloning and expression of progesterone 5beta-reductase (5beta-POR) from Isoplexis canariensis. Planta Med (2006) 0.76
Should pregnant women with substance use disorders be managed differently? Neuropsychiatry (London) (2012) 0.76
Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial. BMC Res Notes (2011) 0.75
Substance abuse/dependence treatment: a European perspective. Subst Abus (2014) 0.75
Austria: investigation likely to have serious consequences. Nature (2008) 0.75
Addiction is a psychiatric disorder - what have we learned from history? Addiction (2012) 0.75
[Electrodermal activity in heroin addicts and patients with methadone and morphine substitution]. Wien Med Wochenschr (2003) 0.75
Opioid Maintenance Treatment--A Call for a Joint European Quality Care Approach. Eur Addict Res (2015) 0.75